Caledonia Investments (CLDN)
London Exchange · UK · prices in GBX · close of 19 Oct 2026
Key indicators
| Last close | GBX 384.00 |
|---|---|
| 52-week range | 308.65 – 402.00 |
| Return, 1 month / 3 months | +1.2% / +1.1% |
| Return, 1 year / 3 years | +3.0% / +26.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 15.5% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 125.47M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Caledonia Investments is an investment trust based in London that manages a portfolio of holdings on behalf of its shareholders. It invests in both quoted and unquoted companies across a range of sectors, including funds and direct holdings in businesses operating in Britain and overseas. The trust is associated with the Cayzer family, whose interests have long been connected with the company, and it operates as a closed-ended investment vehicle.
On this site Caledonia Investments appears as a stock on the London Exchange (UK), code CLDN, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Caledonia Investments (CLDN) trades on the London Exchange in UK. It last closed at GBX 384.00 on 19 October 2026.
Its price-based Market X-Ray is 71 out of 100 (a strong price profile), ranking 455 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.0% and over the last three months it rose 1.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.4% | ||
| From 52-week high | -4.0% | ||
| Momentum | 55 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 1.1% | ||
| 6-month return | 6.2% | ||
| 12-month return, skipping the last month | 1.8% | ||
| Risk (lower is better) | 84 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility (1 year) | 15.5% | ||
| Worst drawdown (1 year) | -19.5% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 125.47M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 46 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Risk (lower is better): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.4% |
|---|---|
| 1 month | +1.2% |
| 3 months | +1.1% |
| 6 months | +6.2% |
| 1 year | +3.0% |
| 3 years | +26.1% |
| 5 years | +23.8% |
Signals
| 50-day / 200-day average | 387.05 / 364.40 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 7.70 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jul 2026 | GBP 0.0400 |
| 4 Dec 2025 | GBP 0.0368 |
| 26 Jun 2025 | GBP 0.5391 |
| 5 Dec 2024 | GBP 0.1969 |
| 27 Jun 2024 | GBP 0.5147 |
| 30 Nov 2023 | GBP 0.1893 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.